noodls browser compatibility check

The security settings of your browser are blocking the execution of scripts.

To use noodls, javascript support must be enabled. Please change your browser's security settings to enable javascript.

If you have changed your browser's security settings, you can click here.

related announcements

News

Healthcare

Targa Resources Corp.

Targa Resources Corp. to Participate in 21st Annual Energy[...]
Raymond James Financial Inc.

Raymond James Financial declares quarterly dividends on common and[...]
SAB Biotherapeutics Inc.

SAB Biotherapeutics Announces Q1 2024 Financial Results and Provides[...]

Phaxiam Therapeutics SA

04/15/2024 | Press release | Distributed by Public on 04/15/2024 01:13

PHAXIAM Therapeutics announces enrolment of the first patient in the phase 1 study for the treatment of endocarditis infections caused by Staphylococcus aureus

Sharing and Personal Tools

Please select the service you want to use:

Smartlinks | Phaxiam Therapeutics SA | News | Health | Science | Research | Finance | Security Markets | Security Markets | Company News | Business Announcement | Products and Services | Securities Issuers | Biotechnology and Medical Research Companies | London Stock Exchange (LSE) | Frankfurt Stock Exchange | Berlin Stock Exchange | Dusseldorf Stock Exchange | Munich Stock Exchange | Stuttgart Stock Exchange | OTC Markets | Tradegate Exchange | NYSE American | NYSE ARCA Equities | Euronext Paris | Nasdaq Capital Market | Cboe BZX Exchange | Cboe BXE Europe | Cboe CXE Europe | Cboe Off Exchange | Cboe BYX Exchange | Cboe EDGA Exchange | Cboe EDGX Exchange | FINRA Alternative Display Facility (ADF) | Aquis Exchange | SIGMA X MTF | Aquis Exchange Europe | Equiduct | Euronext Block MTF | Nasdaq BX | Nasdaq PSX | NYSE Chicago | Turquoise

Back

Download the original document